| |
Follow-up period
|
12 months prior to study entry
|
|---|
|
Measure*
|
Median
|
IQR
|
Median
|
IQR
|
|
Duration of follow-up (years)
|
5.29
|
2.62–8.58
|
-
|
-
|
|
Cumulative duration of GC use (years)
|
0.80
|
0.15–2.56
|
0.23
|
0.05–0.67
|
|
Proportion of follow-up time on GCs (%)
|
26.3
|
3.8–70.0
|
22.7
|
5.4–67.2
|
|
Average dose** (mg)
|
7.5
|
5–15.3
|
10
|
5–20
|
|
Lowest dose** (mg)
|
5
|
2.5–7.5
|
5
|
3–15
|
|
Highest dose** (mg)
|
15
|
7.5–30
|
15
|
6–30
|
-
GC glucocorticoid, IQR interquartile range
-
*Summary statistics were obtained by calculating the value for each patient and then determining median values across the whole population
-
**All doses are prednisolone-equivalent daily doses
